Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Tirzepatide is a dual GIP/GLP-1 receptor agonist marketed by Eli Lilly under the brand names Mounjaro (type 2 diabetes) and Zepbound (chronic weight management)
New Option: TrumpRx.gov (Feb 2026) Medicare members blocked from weight loss coverage can now access Zepbound at ~$346/month through the federal TrumpRx.gov program, which launched February 6, 2026
Sustained delivery of exenatide and other polypeptides
Visual Abstract Text is machine generated and may contain inaccuracies
Providers may review: current medications medical history weight history recovery goals lab work nutrition habits This helps determine whether peptide therapy is appropriate
US$ 26.45
US$ 24.28
US$ 25.16
